IP Verse

Methods For Treating Cancer In Patients With Elevated Levels Of Bim - EP3052131

The patent EP3052131 was granted to Mayo Foundation FOR Medical Education And Research on Dec 5, 2018. The application was originally filed on Sep 3, 2014 under application number EP14850189A. The patent is currently recorded with a legal status of "Opposition Rejected".

EP3052131

MAYO FOUNDATION FOR MEDICAL EDUCATION AND RESEARCH
Application Number
EP14850189A
Filing Date
Sep 3, 2014
Status
Opposition Rejected
Aug 20, 2021
Grant Date
Dec 5, 2018
External Links
Slate, Register, Google Patents

Patent Summary

Patent Family

Patent Family

Patent Oppositions (2)

Patent oppositions filed by competitors challenge the validity of a granted patent. These oppositions are typically based on claims of prior art, lack of novelty, or non-obviousness. They are a key part of the process for determining a patent's strength and enforceability.

CompanyOpposition DateRepresentativeOpposition Status

Get instant alerts for new oppositions and patent status changes

PFIZERSep 5, 2019MASCHIO & SOAMESADMISSIBLE
MERCK PATENTSep 4, 2019-ADMISSIBLE

Patent Citations (21) New

Patent citations refer to prior patents cited during different phases such as opposition or international search.

Citation PhasePublication NumberPublication Link
DESCRIPTIONUS4816567
DESCRIPTIONUS4935496
DESCRIPTIONUS5502167
DESCRIPTIONUS5530101
DESCRIPTIONUS5558864
DESCRIPTIONUS5565332
DESCRIPTIONUS5585089
DESCRIPTIONUS5639641
DESCRIPTIONUS5693493
DESCRIPTIONUS5693761
DESCRIPTIONUS5693762
DESCRIPTIONUS5698417
DESCRIPTIONUS5705154
DESCRIPTIONUS5733743
DESCRIPTIONUS5750078
DESCRIPTIONUS5770403
DESCRIPTIONWO2013090552
INTERNATIONAL-SEARCH-REPORTUS2009304711
INTERNATIONAL-SEARCH-REPORTUS2010285039
OPPOSITIONWO2014144666
SEARCHWO2013090552

Non-Patent Literature (NPL) Citations (53) New

NPL citations refer to non-patent references such as research papers, articles, or other publications cited during examination or opposition phases.

Citation PhaseReference TextLink
DESCRIPTION- ALLIE et al., J. Immunol., (20110000), vol. 186, pages 6280 - 6286-
DESCRIPTION- BALDRICK, Regul. Toxicol. Pharmacol., (20000000), vol. 32, pages 210 - 218-
DESCRIPTION- BERRIEN-ELLIOT MM et al., Cancer Research, (20130115), vol. 73, no. 2, pages 605 - 616-
DESCRIPTION- CHARMAN, J. Pharm. Sci., (20000000), vol. 89, pages 967 - 978-
DESCRIPTION- DONG et al., Immunity, (20040000), vol. 20, pages 327 - 336-
DESCRIPTION- "GENBANK°", Database accession no. AAF25807-
DESCRIPTION- "GENBANK", Database accession no. AAH74740.1-
DESCRIPTION- "GENBANK", Database accession no. AF177937-
DESCRIPTION- "GENBANK", Database accession no. BC074740.2-
DESCRIPTION- GERDES et al., J. Immunol., (19840000), vol. 133, pages 1710 - 1715-
DESCRIPTION- GIBBONS et al., Oncolmmunology, (20120000), vol. 1, no. 7, pages 1061 - 1073-
DESCRIPTION- GIBBONS RM et al., Oncoimmunology, (20121001), vol. 1, no. 7, pages 1061 - 1073-
DESCRIPTION- GRIVENNIKOV et al., Cell, (20100000), vol. 140, pages 883 - 899-
DESCRIPTION- HIRANO et al., Cancer Res., (20050000), vol. 65, pages 1089 - 1096-
DESCRIPTION- HOLLINGER et al., Proc. Natl. Acad. Sci. USA, (19930000), vol. 90, pages 6444 - 6448-
DESCRIPTION- HOLT et al., Trends Biotechnol., (20030000), vol. 21, pages 484 - 90-
DESCRIPTION- JACINTO et al., Cell, (20060000), vol. 127, pages 125 - 137-
DESCRIPTION- JAYARAMAN, J. Immunol. Methods, (20050000), vol. 306, pages 68 - 79-
DESCRIPTION- JONES et al., Nature, (19860000), vol. 321, page 522-
DESCRIPTION- JONES et al., Nature, (19860000), vol. 321, pages 522 - 525-
DESCRIPTION- KONIECZNY et al., Haematologia (Budap.), (19810000), vol. 14, page 95-
DESCRIPTION- MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, page 6851-
DESCRIPTION- MORRISON et al., Proc. Natl. Acad. Sci. USA, (19840000), vol. 81, pages 6851 - 6855-
DESCRIPTION- MUYLDERMANS et al., Rev. Mol. Biotechnol., (20010000), vol. 74, pages 277 - 302-
DESCRIPTION- "NCBI", Database accession no. NM_005191.3-
DESCRIPTION- "NCBI", Database accession no. NP 005182.1-
DESCRIPTION- PARK et al., Blood, (20100000), vol. 116, pages 1291 - 1298-
DESCRIPTION- PLUCKTHUN, The Pharmacology of Monoclonal Antibodies, Springer Verlag, (19940000), vol. 113, pages 269 - 315-
DESCRIPTION- POWELL et al., PDA J. Pharm. Sci. Technol., (19980000), vol. 52, pages 238 - 311-
DESCRIPTION- PRESTA, Curr. Op. Struct. Biol., (19920000), vol. 2, pages 593 - 596-
DESCRIPTION- QI et al., J. Biol. Chem., (20060000), vol. 281, pages 813 - 823-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, page 323-
DESCRIPTION- RIECHMANN et al., Nature, (19880000), vol. 332, pages 323 - 329-
DESCRIPTION- SARBASSOV et al., Science, (20050000), vol. 307, pages 1098 - 1101-
DESCRIPTION- TOPALIAN SL et al., The New England Journal of Medicine, (20120628), vol. 366, no. 26, pages 2443 - 2454-
DESCRIPTION- WANG, Int. J. Pharm., (20000000), vol. 203, pages 1 - 60-
EXAMINATION- DRONCA ROXANA S ET AL, "BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma.", IMMUNOTHERAPY DEC 2016, (201612), vol. 8, no. 12, ISSN 1750-7448, pages 1351 - 1353-
EXAMINATION- DRONCA ROXANA S ET AL, "T cell Bim levels reflect responses to anti-PD-1 cancer therapy.", JCI INSIGHT 05 MAY 2016, (20160505), vol. 1, no. 6-
INTERNATIONAL-SEARCH-REPORT- GIBBONS ET AL., "B7-H1 limits the entry of effector CD 8+ T cells to the memory pool by upregulating Bim.", ONCOIMMUNOLOGY, (2012), vol. 1, no. 7, pages 1061 - 1073, XP055332328
OPPOSITION- JOHNSON et al., N Engl J Med., (20161103), vol. 375, no. 18, pages 1749 - 1755-
OPPOSITION- LIU et al., "Endogenous tumor-reactive CD 8+ T cells are differentiated effector cells expressing high levels of CD 11 a and PD-1 but are unable to control tumor growth", Oncolmmunology, (20130600), vol. 2, no. 6, pages 1 - 12, XP055638478-
OPPOSITION- LIU et al., "Endogenous tumor-reactive CD 8+ T cells are differentiated effector cells expressing high levels of CD 11 a and PD-1 but are unable to control tumor growth", Oncolmmunology, (20130601), vol. 2, no. 6, pages 1 - 12, XP055638478-
OPPOSITION- TOPALIAN et al., "Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer", N Engl J Med, (20120600), vol. 366, no. 26, pages 2443 - 2454, XP055098235
OPPOSITION- TOPALIAN, S. et al., "Safety, Activity, and Immune Correlates of Anti-PD-1 Antibody in Cancer", NEJM, (20120600), vol. 366, no. 26, doi:10.1056/NEJMoa1200690, pages 2443 - 2454, XP055098235
OPPOSITION- DRONCA et al., "T cell Bim levels reflect responses to anti-PD-1 cancer therapy", JO Insight, (20160000), vol. 1, no. 6, XP002788154
OPPOSITION- DRONCA, R. et al., "T cell Bim levels reflect responses to anti-PD-1 cancer therapy", JCI insight, (20160500), vol. 1, no. 6, doi:10.1172/jci.insight.86014, pages e86014 - 1 - 14, XP002788154
OPPOSITION- DONG et al., "a novel method for identifying downstream signals in tumor-reactive T cells following PD-1 engagement and monitoring endogenous tumor immunity and immunotherapy", Journal of Clinical Oncology, (20140520), vol. 32, no. 15, XP055638824
OPPOSITION- DRONCA et al., "BCL-2-interacting mediator of cell death (Bim) is a novel biomarker for response to anti-PD-1 therapy in patients with advanced melanoma", Immunotherapy, (20161200), vol. 8, no. 12, doi:10.2217/imt-2016-0100, pages 1351 - 1353, XP002788155
OPPOSITION- GIBBONS et al., "B7-H1 limits the entry of effector CD 8+ T cells to the memory pool by upregulating Bim", Oncoimmunology, (20120000), vol. 1, no. 7, pages 1061 - 1073, XP055332328
OPPOSITION- GIBBONS R. et al., "B7-H1 limits the entry of effector CD 8+ T cells to the memory pool by upregulating Bim", Oncolmmunology, (20121000), vol. 1, no. 7, doi:10.4161/onci.20850, pages 1061 - 1073, XP055332328
SEARCH- TOPALIAN SUZANNE L ET AL, "Safety, activity, and immune correlates of anti-PD-1 antibody in cancer.", THE NEW ENGLAND JOURNAL OF MEDICINE 28 JUN 2012, (20120628), vol. 366, no. 26, ISSN 1533-4406, pages 2443 - 2454, XP002767416 [X] 1-10 * page 2452; figure B *
SEARCH- BERRIEN-ELLIOTT MELISSA M ET AL, "Durable adoptive immunotherapy for leukemia produced by manipulation of multiple regulatory pathways of CD8+ T-cell tolerance.", CANCER RESEARCH 15 JAN 2013, (20130115), vol. 73, no. 2, ISSN 1538-7445, pages 605 - 616, XP002767417 [A] 1-10 * page 606, column left * * page 608, column right *
SEARCH- RACHEL M GIBBONS ET AL, "B7-H1 limits the entry of effector CD8 + T cells to the memory pool by upregulating Bim", ONCOIMMUNOLOGY, (20121001), vol. 1, no. 7, doi:10.4161/onci.20850, pages 1061 - 1073, XP055332328 [A] 1-10 * abstract *

Download Citation Report

Get a free citation report including examiner, opposition, and international search citations.

Get Citation Report

Dossier Documents

The dossier documents provide a comprehensive record of the patent’s prosecution history - including filings, correspondence, and decisions made by patent offices - and are crucial for understanding the patent’s legal journey and any challenges it may have faced during examination.

  • Date

    Description

  • Get instant alerts for new documents